WithdrawnNot Applicable

Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.

Stopped: the hypothesis of the research could not be confirmed during the initial phase of the research

0Started 2023-09

Plain-language summary

Chronic pain symptoms can lead to sleep and mood disorders, restrict domestic and work activities and have a significant impact on quality of life. The prevalence of chronic pain in the general population varies between 10 and 52% depending on the study, 7% of which is neuropathic pain. Anxiety-depression comorbidities are found in a large number of patients, with harmful consequences on pain since they exacerbate symptoms and their repercussions. Conversely, pain increases psychological distress. Ketamine has been used in the context of depressive episodes for its rapid action. It is also increasingly used in chronic pain due to its ability to regulate the "wind-up" effect, a phenomenon involved in the central hypersensitization that is inevitably present in neuropathic pain of prolonged duration. Several studies have found electroencephalographic (EEG) signatures associated with a good antidepressant response to Ketamine. The frequency, absolute and relative power and cordance of the EEG signal in certain frequency ranges (theta, alpha, beta and gamma) could be useful to guide and adapt therapies for depression and pain.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients \> 18 years old * Eligible for Ketamine infusions in the context of chronic pain refractory to usual therapies * Patient informed and having expressed his non-objection to participation in this research * Patient who is not subject to a legal protection measure Exclusion Criteria: * Patients under 18 years of age. * Patients with a contraindication to ketamine. * Patient opposed to protocol participation * Pregnant woman * Patient under legal protection * Patient not affiliated to a social security scheme

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Characterizing the EEG signature of chronic pain patients before and during intravenous Ketamine infusion

Timeframe: Week 3

Trial details

NCT IDNCT05949554

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-09

View on ClinicalTrials.gov More Neuropathic Pain trials